Management Team

Gregory D. Casciaro

President and Chief Executive Officer

Gregory D. Casciaro has served as XTENT's President, Chief Executive Officer and a member of XTENT's board of directors since September 2004. From February 2000 to August 2003, Mr. Casciaro was the President and Chief Executive Officer and a director of Orquest, a medical technology company acquired by Johnson & Johnson. His career includes positions with General Surgical Innovations (acquired by United States Surgical) and vice president of sales for Guidant Corporation. Mr. Casciaro holds a B.A. in Business Administration from Marquette University.

Timothy D. Kahlenberg

Chief Financial Officer

Timothy D. Kahlenberg has served as XTENT's Chief Financial Officer since April 2006. From May 2005 to April 2006, Mr. Kahlenberg was the director of finance at Medtronic, a medical technology company. From August 1999 to February 2004, Mr. Kahlenberg was the President and Chief Financial Officer of LuMend, a developer of medical devices to treat chronic total occlusions, which was acquired by Cordis Corporation, a Johnson & Johnson company, in September 2005. Previous positions include senior financial and operating posts at AneuRx, a division of Medtronic, and at DVI, a subsidiary of Guidant Corp. Mr. Kahlenberg holds a B.S. in Quantitative Business Analysis and an M.B.A. from Indiana University.

Bernard H. Andreas

Vice President, Innovation & Concept Development

Bernard H. Andreas is one of XTENT's founders and has served as XTENT's Vice President of Innovation and Concept Development since April 2008. From January 2006 to March 2008, Mr. Andreas served as XTENT's Vice President of Research and Development. From October 2002 to December 2005, Mr. Andreas served as XTENT's Engineering Director of Research and Development. From May 2000 to September 2002, Mr. Andreas served as the Engineering Director of Research and Development at The Foundry, a medical device incubator, where he contributed to the conception, evaluation and development of XTENT's custom-length stent technology. Mr. Andreas holds a B.S. in Mechanical Engineering and Materials Science from the University of California, Davis.

Randolph E. Campbell

Chief Technical Officer

Randolph E. Campbell has served as XTENT's Chief Technical Officer since April 2004. From October 2001 to April 2004, Mr. Campbell served as the Vice President of Manufacturing at Emphasys Medical, a developer of medical devices for the treatment of chronic obstructive pulmonary disease. From January 1994 to September 2001, Mr. Campbell was the Vice President of Operations at Perclose, a developer of vascular access closure devices, which was acquired by Abbott Laboratories in November 1999. Mr. Campbell holds a B.S. in Chemical Engineering from the University of California, Berkeley.

Anne-Marie Hodkinson

Vice President, Human Resources

Anne-Marie Hodkinson has served as XTENT's Vice President of Human Resources since June 2007. From March 2006 to June 2007, Ms. Hodkinson served as Director of Human Resources at Cytyc Corporation, where she was responsible for the global human resources management of the Surgical Products Business Unit, overseeing more than 600 employees and $350 million in annual revenue. From October 1999 to March 2006, Ms. Hodkinson held the position of Director, Human Resources at Medtronic where she supported the coronary, endovascular and peripheral business units, as well as a variety of corporate development initiatives in the clinical, quality and regulatory arena. Ms. Hodkinson holds a B.S. in Business Administration from California Polytechnic State University, Pomona, and an M.S. in Human Resources and Organizational Development from the University of San Francisco.

Philippe H. Marco, M.D.

Vice President, Quality Assurance, Clinical and Regulatory Affairs

Philippe H. Marco, M.D. has served as XTENT's Vice President of Quality Assurance, Clinical and Regulatory Affairs since January 2003. From July 1996 to December 2002, Dr. Marco served as the Director of Medical Affairs at Perclose. Following the acquisition of Perclose by Abbott Laboratories, Dr. Marco was responsible for worldwide clinical and regulatory affairs for Abbott Laboratories' cardiovascular device division. Dr. Marco holds a M.D. from the University of Limoges and the University of Toulouse and completed a fellowship at the Pacific Foundation for Cardiovascular Research at Sequoia Hospital.